Auswahl wichtiger Publikationen der Medizinischen Klinik A

  • Schmitt A, Grimm M, Kreienkamp N, Junge H, Labisch J, Schuhknecht L, Schönfeld C, Görsch ES, Tibello A, Menck K, Bleckmann A, Lengerke C, Rosenbauer F, Grau M, Zampieri M, Schulze-Osthoff K, Klener P, Dolnikova A, Lenz G, Hailfinger S. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood. 2023 Jun 9:blood.2022019274. doi: 10.1182/blood.2022019274. Epub ahead of print. PMID: 37294920.

 

 

  • Bäumer, N.*, Scheller, A.*, Wittmann, L., Faust, A., Apel, M., Nimmagadda, S.C., Geyer, C., Grunert, K., Kellmann, N., Peipp, M., Kailayangiri, S., Gutierrez Suburu, M.E., Strassert, C.A., Schenk, M., Greune, L., Rüter, C., Dersch, P., Hartmann, W., Rossig, C., Neri, D., Müller-Tidow, C., Schwöppe, C., Schliemann, C., Khandanpour, C., Lenz, G., Berdel, W.E., Bäumer, S. Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. J Hematol Oncol. 15, 171 (2022).

 

  • Bäumer, N., Tiemann, J., Scheller, A., Meyer, T., Wittmann, L., Suburu, M. E. G., Greune, L., Peipp, M., Kellmann, N., Gumnior, A., Brand, C., Hartmann, W., Rossig, C., Müller-Tidow, C., Neri, D., Strassert, C. A., Rüter, C., Dersch, P., Lenz, G., Koeffler, H. P., Berdel, W. E., Bäumer, S. Targeted siRNA nanocarrier: a platform technology for cancer treatment. Oncogene 41, 2210–2224 (2022).

 

  • Faust, A.*, Bäumer, N.*, Schlütermann, A., Becht, M., Greune, L., Geyer, C., Rüter, C., Margeta, R., Wittmann, L., Dersch, P., Lenz, G., Berdel, W.E., Bäumer, S. Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs). Angew Chem Int Ed Engl. 2022: e202109769.

 

 

 

  • Schmitt A, Xu W, Bucher P, Grimm M, Konantz M, Horn H, Zapukhlyak M, Berning P, Brändle M, Jarboui MA, Schönfeld C, Boldt K, Rosenwald A, Ott G, Grau M, Klener P, Vockova P, Lengerke C, Lenz G, Schulze-Osthoff K, Hailfinger S. Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL. Blood. 2021 Sep 9;138(10):871-884. doi: 10.1182/blood.2020009404. PMID: 33876201.

 

  • Bucher P, Erdmann T, Grondona P, Xu W, Schmitt A, Schürch C, Zapukhlyak M, Schönfeld C, Serfling E, Kramer D, Grau M, Klener P, Lengerke C, Schulze-Osthoff K, Lenz G, Hailfinger S. Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood. 2020 Jan 9;135(2):121-132. doi: 10.1182/blood.2019001866. PMID: 31794606.

 

 

  • Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE. First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumors: results of a phase I dose escalation study. Cancers. Vol. 12: 1488 (2020). doi: 10.3390/cancers 12061488.
  • Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Ráčil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. J Clin Oncol. 2019 Oct 10;37(29):2632-2642. doi: 10.1200/JCO.19.00416. Epub 2019 Aug 20.

 

 

 

 

  • Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF. Reptin drives tumour progression and resistance to chemotherapy in non-small cell lung cancer. Eur Respir J 2018, May 31. pii: 1701637.

 

  • Stucke-Ring J, Ronnacker J, Brand C, Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wünsch B, Müller-Tidow C, Mesters RM, Schwöppe C, Berdel WE. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. Oncotarget. Vol. 7, 50 (2016): 82458-82472. doi: 10.18632/oncotarget.12559.

 

 

  • Arteaga MF, Mikesch JH, Qiu J, Christensen J, Helin K, Kogan SC, Dong S, So CW. The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia.Cancer Cell; 23,1-14, March 18, 2013.

 

 

 

  • Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM. Stromal gene signatures in large-B-cell lymphomas.N Engl J Med 2008 Nov 27; 359 (22): 2313-23.